Efficiency of tiotropium bromide in patients with severe persistent bronchial asthma in clinical practice

Résumé fourni par la source

The aim of the study was to investigate the effectiveness of tiotropium bromide in patients with severe persistent asthma under conditions of real clinical practice. The study group included 20 outpatients who, despite the maximum volumes of basic therapy, maintained an uncontrolled course of the disease. In addition to previous therapy, patients were given tiotropium bromide 5 mg per day. The study lasted five months. During this period, clinical symptoms, the presence of exacerbations of asthma, spirometry parameters, the level of disease control according to the questionnaire Asthma Control Questionnaire™ (ACQ-5) and the quality of life of patients were monthly evaluated. It has been found that the inclusion of tiotropium bromide in the treatment regimen causes a significant improvement in asthma control, the ACQ-5 index decreased by 48 %. There was also a significant dynamics of postbronchodilation FEV1 and quality of life indicators. None of the patients had a worsening of the disease during the observation period. However, in order to achieve a therapeutic effect, systematic tiotropium bromide therapy was required for at least three months. The results obtained confirmed the positive effect of tiotropium bromide on the control of asthma and the quality of life.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.